



Schweizerische Pädiatrische Onkologie Gruppe
Groupe d'Oncologie Pédiatrique Suisse
Gruppo d'Oncologia Pediatrica Svizzera
Swiss Paediatric Oncology Group

Relapsed AML 2009 Registry

Acute myeloid leukaemia (AML) is a form of blood cancer that is rare in children and adolescents. Over the last few decades, the prospects of cure have already been considerably improved, but experience in the treatment of relapses of AML is limited. Despite intensive chemotherapy and stem cell transplantation, only about one third of these patients survive the next 5 years without any indications of a recurrence. The University Children's Hospital III Essen in Germany is responsible for the international implementation of the study (sponsor). In Switzerland, the Swiss Paediatric Oncology Group (SPOG) is responsible for the conduct of the study (sponsor representative).

The objectives of the AML Registry 2009 are to record such relapses, to ensure high-quality treatment advice, to identify risk factors, to develop new methods of diagnosis and to support biological and clinical research projects. The treating centers can contact the responsible study center for specific questions and receive information about similar cases from other participating clinics. In this way, patients benefit from second opinions from experienced expert groups. In parallel, accompanying scientific studies are planned to investigate the biology and behaviour of leukaemia cells in the blood and bone marrow. The aim is to make the diagnosis more reliable, improve the biological understanding of the disease and find new therapeutic approaches.

Contact details for the sponsor representative in Switzerland:

Partner Relations
SPOG Coordinating Center
Effingerstrasse 33
3008 Bern
Phone: +41 31 389 91 89